This is a YMYL article on a fast-evolving clinical topic \u2014 anaesthesia guidance on GLP-1 medications has changed several times since 2023. Your surgeon, anaesthesiologist and the doctor who prescribed your Mounjaro are the authoritative sources for your specific case. The guidance below reflects current consensus from the American Society of Anesthesiologists (ASA)<\/a>, the Association of Anaesthetists of Great Britain and Ireland (AAGBI), and major surgical societies \u2014 but it is general patient information, not personal medical advice.<\/p>\n\n\n\n For tummy tuck under general anaesthesia, Mounjaro should be stopped at least 1 week (one missed weekly dose) before surgery, per ASA 2023 guidance for once-weekly GLP-1 medications<\/strong> \u2014 some surgeons request longer (up to 2 weeks) and some now use individualised approaches based on dose and gastric ultrasound. The reason is anaesthesia safety: Mounjaro delays gastric emptying, increasing the risk of stomach content being present during anaesthetic induction and causing aspiration. Beyond the anaesthesia stop, weight loss should be stable for 2\u20133 months before surgery \u2014 patients still actively losing weight at the time of tummy tuck have a higher risk of suboptimal long-term contour as the body composition continues to change. Mounjaro can usually be resumed 1\u20132 weeks post-op once normal eating is tolerated. Your surgeon and the doctor who prescribed your Mounjaro must agree the timeline.<\/p>\n\n\n\n Mounjaro is the brand name for tirzepatide<\/strong>, a once-weekly injectable medication developed by Eli Lilly. It is a dual GIP and GLP-1 receptor agonist \u2014 meaning it activates two gut hormone pathways simultaneously. Tirzepatide is approved for type 2 diabetes (under the Mounjaro brand in many markets) and for weight management (under the brand Zepbound in some markets; Mounjaro is used off-label or via private prescription for weight loss in others, including the UK).<\/p>\n\n\n\n The clinical effect: tirzepatide reduces appetite, increases satiety after meals, and significantly slows gastric emptying. Average weight loss in clinical trials at full dose has been around 15\u201322% of body weight over a year \u2014 making it one of the most effective non-surgical weight loss treatments available. It is delivered as a once-weekly subcutaneous injection, usually self-administered.<\/p>\n\n\n\n Related medications in the same family include semaglutide<\/strong> (Ozempic for diabetes, Wegovy for weight management), liraglutide<\/strong> (Saxenda \u2014 daily injection), and others. The pre-op principles in this guide apply to all of them, with some differences in timing covered below.<\/p>\n\n\n\n A few combined trends explain why so many tummy tuck patients are now on Mounjaro:<\/p>\n\n\n\n However, the combination requires careful timing. The benefits of Mounjaro (weight loss) and the risks (anaesthesia complications) operate on different timelines that need to be planned around the surgery date.<\/p>\n\n\n\n The reason to stop Mounjaro before surgery isn’t the weight loss \u2014 it’s the gastric effect.<\/strong> Tirzepatide and other GLP-1 medications significantly slow gastric emptying. This means food (or even fluid) can remain in the stomach much longer than usual after eating. During the induction of general anaesthesia, residual stomach contents can be regurgitated and inhaled into the lungs \u2014 known as aspiration \u2014 which can cause aspiration pneumonia or, rarely, more serious airway complications. Standard pre-op fasting (no food for 6 hours, clear fluids up to 2 hours) was designed assuming normal gastric emptying. On Mounjaro, that assumption no longer holds.<\/p>\n\n\n\n Several anaesthesia case reports between 2022 and 2024 documented residual gastric content in patients on GLP-1 medications who had followed standard fasting protocols. These reports prompted updated guidance from anaesthesia societies. The risk is procedure-independent \u2014 it applies to any surgery under general anaesthesia or deep sedation, including tummy tuck.<\/p>\n\n\n\n Current consensus guidance, with some evolution:<\/p>\n\n\n\n Your anaesthesiologist makes the final call. If you’re a tummy tuck patient in Turkey, your clinic’s anaesthesia team will give you specific instructions \u2014 typically asking you to miss at least one weekly Mounjaro dose, and sometimes more, before surgery. Do not stop or change your Mounjaro dose without consulting both your prescriber and the surgical team.<\/strong><\/p>\n\n\n\n The other reason to think carefully about Mounjaro and tummy tuck timing is the result quality, not just anaesthesia safety. Tummy tuck is a body contouring procedure that removes loose skin and tightens the abdominal wall. If your body is still actively losing weight at the time of surgery \u2014 and continues losing afterward \u2014 the result you’ve paid for can be undermined:<\/p>\n\n\n\n This is why most surgeons request a weight-stable period before booking tummy tuck. Mounjaro patients should think of the pathway as: reach target weight \u2192 stabilise for 2\u20133 months \u2192 stop Mounjaro per anaesthesia guidance \u2192 surgery<\/strong>.<\/p>\n\n\n\n Putting weight optimisation, weight stability and Mounjaro cessation together gives an idealised timeline. Yours will be individualised:<\/p>\n\n\n\n Active weight loss under your prescriber’s supervision. Reach the BMI window your surgeon has set for tummy tuck (typically 22\u201330; sometimes up to 32 with optimisation).<\/p>\n\n\n\n Maintain target weight for at least 8\u201312 weeks. Mounjaro may continue at maintenance dose during this period, per your prescriber. Surgical team confirms BMI is in range and weight is stable.<\/p>\n\n\n\n Standard pre-op work-up (bloods, ECG, anaesthesia review). Stop smoking if you haven’t already. Medical clearance<\/a> finalised.<\/p>\n\n\n\n Last Mounjaro dose at least 1 week before surgery (some surgeons request 2 weeks). Confirm with both your surgeon’s anaesthesia team and your prescribing doctor before changing the dose.<\/p>\n\n\n\n Follow standard pre-op fasting plus any extended fasting protocol the anaesthesia team requests. Disclose all medications honestly during pre-op check-in.<\/p>\n\n\n\n Soft diet, gradual normal eating, healing protein priority. Mounjaro typically held while you’re transitioning back to normal eating.<\/p>\n\n\n\n Once you’re eating normally, healing is on track, and your surgeon and prescriber agree, Mounjaro can typically be resumed at maintenance dose. Some patients are advised to restart at a lower dose to re-acclimatise.<\/p>\n\n\n\n Resuming too early can cause nausea (which is uncomfortable with abdominal incisions) and may reduce protein\/calorie intake needed for wound healing. Resuming too late may allow some weight rebound. Typical guidance:<\/p>\n\n\n\n Many patients resume Mounjaro between week 2 and week 4 post-op. Some patients who reached their goal weight choose to discontinue Mounjaro at this point (with prescriber guidance) and rely on their new lifestyle habits to maintain. Others continue at maintenance dose long-term.<\/p>\n\n\n\n Aspiration pneumonia.<\/strong> Residual gastric content during anaesthetic induction can be inhaled into the lungs, causing chemical pneumonitis or bacterial pneumonia. Can be serious. The reason for the cessation guidance.<\/p>\n\n\n\n Increased post-op nausea and vomiting.<\/strong> Vomiting after abdominal surgery is uncomfortable and risks strain on the new abdominal closure.<\/p>\n\n\n\n Concealing Mounjaro use is dangerous.<\/strong> Patients sometimes don’t disclose GLP-1 medication use because they’re embarrassed or worried surgery will be delayed. Anaesthesiologists need to know \u2014 for your safety. Disclosure is the right answer, always. If you’ve taken Mounjaro within the previous week, tell your anaesthesia team. They may delay surgery, modify the plan, or use ultrasound to assess your stomach contents \u2014 all of which are safer than concealment.<\/p>\n\n\n\n Broadly yes \u2014 these are all GLP-1 (or GLP-1\/GIP) medications that slow gastric emptying. Specific timing:<\/p>\n\n\n\nTable of contents<\/h3>\n\n\n\n
\n
The short answer<\/h2>\n\n\n\n
What is Mounjaro (tirzepatide)?<\/h2>\n\n\n\n
Why Mounjaro before tummy tuck is common in 2026<\/h2>\n\n\n\n
\n
The clinical issue: delayed gastric emptying<\/h2>\n\n\n\n
How long to stop Mounjaro before surgery<\/h2>\n\n\n\n
\n
![\"Mounjaro](\"https:\/\/revitalizeinturkey.com\/wp-content\/uploads\/2026\/05\/mounjaro-before-tummy-tuck-infographic-519x1024.jpg\" "\\"\\"")
Why weight stability matters more than weight loss<\/h2>\n\n\n\n
\n
The combined pre-op timeline<\/h2>\n\n\n\n
Months -12 to -3: Mounjaro for weight optimisation<\/h3>\n\n\n\n
Months -3 to -1: Weight stability<\/h3>\n\n\n\n
Weeks -2 to -1: Final pre-op preparation<\/h3>\n\n\n\n
Week -1 (or earlier): Stop Mounjaro<\/h3>\n\n\n\n
Day 0: Surgery<\/h3>\n\n\n\n
Weeks 1\u20132 post-op: No Mounjaro yet<\/h3>\n\n\n\n
Week 2\u20134 post-op: Resume Mounjaro per medical advice<\/h3>\n\n\n\n
When to resume Mounjaro after tummy tuck<\/h2>\n\n\n\n
\n
Risks of not stopping Mounjaro<\/h2>\n\n\n\n
Ozempic, Wegovy, Saxenda \u2014 same principles?<\/h2>\n\n\n\n